Marketing execs at Fujifilm Medical Systems USA have revamped the company's pricing models for PACS in hopes of extending the reach of Synapse. Fuji's new volume-based site license model considers procedure volume and planned concurrency of use, allowing
Marketing execs at Fujifilm Medical Systems USA have revamped the company's pricing models for PACS in hopes of extending the reach of Synapse. Fuji's new volume-based site license model considers procedure volume and planned concurrency of use, allowing customers unlimited use of the Synapse application, regardless of the number of servers, workstations, and modalities that may be in use. Children's Hospital in Boston has already taken advantage of the pricing scheme to make Synapse available on more than 3000 desktops.
A different Fuji program has been designed to meet the needs of smaller facilities conducting fewer than 45,000 radiological studies per year. The turnkey solution, dubbed the Single Step to Digital program, offers three individual purchase packages combining Synapse, Fuji Computed Radiography, and Fuji DryPix imagers. Options include the purchase of just Synapse, Synapse with Fuji's XG5000 and DryPix 5000, or Synapse with the SmartCR and DryPix 3000.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.